| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6241456 | Respiratory Medicine | 2015 | 9 Pages |
Abstract
The results from these two studies demonstrate that the addition of umeclidinium (62.5 μg and 125 μg) to FF/VI (100/25 μg) provides statistically significant and clinically meaningful improvements in lung function compared with placebo + FF/VI in patients with COPD. Statistically significant improvements in quality of life with UMEC + FF/VI versus placebo + FF/VI were reported in one study only. Safety profiles were consistent across all treatment groups in both studies. These studies support the use of triple therapy in COPD, providing physicians with an alternative treatment option.
Keywords
VilanterolUMECPBOUmeclidiniumSGRQSAEMedDRAHRQOLFluticasone furoateICSFVCFEV1CATASEQOLQuality of lifeLAMACOPD Assessment Testlong-acting muscarinic antagonistRun-inITTBronchodilationCOPDChronic obstructive pulmonary diseaseforced expiratory volume in one secondMedical Dictionary for Regulatory ActivitiesLABAGlobal Initiative for Chronic Obstructive Lung DiseaseGoldforced vital capacityadverse eventSerious adverse eventconfidence intervalIntent-to-treatpatient-reported outcomePROweighted meanSt George's Respiratory QuestionnairePlaceboLeast squaresInhaled corticosteroidHealth-related quality of life
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Thomas M. Siler, Edward Kerwin, Ana R. Sousa, Alison Donald, Rehan Ali, Alison Church,